Details for Patent: 6,048,899

Title:	Anticonvulsant enantiomeric amino acid derivatives
Abstract:	The present invention is directed to N-benzyl-2-amino-3-methoxypropionamide and stereoisomers the use thereof anti-convulsant and an intermediate in the preparation of other anti-convulsants.
Inventor(s):	Kohn; Harold (Houston, TX), Andurkar; Shridhar V. (Houston, TX)
Assignee:	Research Corporation Tech., Inc. (Tucson, AZ)
Filing Date:	Jun 29, 1998
Application Number:	09/107,206
Claims:	1. A compound of the formula: ##STR8## or pharmaceutically acceptable salts thereof. 2. The compound of claim 1 which is in the R configuration. 3. A substantially pure compound of claim 1. 4. A substantially pure compound of claim 2. 5. The compound of claim 2 which is substantially enantiopure. 6. A pharmaceutical composition comprising an anti-convulsant effective amount of the compound according to claim 1 and a pharmaceutical carrier therefor. 7. The pharmaceutical composition according to claim 6 wherein said compound is in the R-configuration. 8. The pharmaceutical composition according to claim 6 wherein said compound is substantially pure. 9. The pharmaceutical composition according to claim 7 wherein said compound is substantially pure. 10. The pharmaceutical composition according to claim 7 wherein the compound is substantially enantiopure. 11. A method of treating central nervous system disorders in an animal comprising administering to said animal in need thereof an anti-convulsant effective amount of a compound according to claim 1. 12. The method according to claim 11 wherein the compound is in the R configuration. 13. The method according to claim 11 wherein the animal is a mammal. 14. The method according to claim 13 wherein the mammal is human. 15. The method according to claim 12 wherein the animal is a mammal. 16. The method according to claim 15 wherein the mammal is human. 17. The method according to claim 11 wherein the compound is substantially pure. 18. The method according tc claim 12 wherein the compound is substantially pure. 19. The method according to claim 12 wherein the compound is substantially enantiopure.